BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hodroj MH, Bou-fakhredin R, Nour-eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood Reviews 2019;37:100585. [DOI: 10.1016/j.blre.2019.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lee YC, Yen CT, Lee YL, Chen RJ. Thalassemia Intermedia: Chelator or Not? Int J Mol Sci 2022;23:10189. [PMID: 36077584 DOI: 10.3390/ijms231710189] [Reference Citation Analysis]
2 Elfaituri MK, Ghozy S, Ebied A, Morra ME, Hassan OG, Alhusseiny A, Abbas AS, Sherif NA, Fernandes JL, Huy NT. Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. Vox Sang 2021. [PMID: 33634883 DOI: 10.1111/vox.13083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Maffei L, Sorrentino F, Caprari P, Taliani G, Massimi S, Risoluti R, Materazzi S. HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives. Front Mol Biosci 2020;7:7. [PMID: 32118034 DOI: 10.3389/fmolb.2020.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert Review of Hematology 2020;13:85-94. [DOI: 10.1080/17474086.2020.1686354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]